Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy | Zendy

Ryan K Dare | Zendy; Chad Tewell | Zendy; Bryan Harris | Zendy; Patty W. Wright | Zendy; Sara L. Van Driest | Zendy; Eric FarberEger | Zendy; George E. Nelson | Zendy; Thomas R. Talbot | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy

Author(s) -

Ryan K Dare,

Chad Tewell,

Bryan Harris,

Patty W. Wright,

Sara L. Van Driest,

Eric FarberEger,

George E. Nelson,

Thomas R. Talbot

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy287

Subject(s) - daptomycin , medicine , statin , hydroxymethylglutaryl coa reductase inhibitors , myopathy , simvastatin , atorvastatin , pharmacology , vancomycin , biology , bacteria , genetics , staphylococcus aureus

Daptomycin-associated myopathy has been identified in 2%-14% of patients, and rhabdomyolysis is a known adverse effect. Although risk factors for daptomycin-associated myopathy are poorly defined, creatine phosphokinase (CPK) monitoring and temporary discontinuation of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or "statins," has been recommended.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research